Your browser doesn't support javascript.
Metformin - a new approach.
Cwynar-Zajac, Lucja.
  • Cwynar-Zajac L; Chair and Department of Basic Medical Sciences, Wroclaw Medical University, Wroclaw, Poland.
Pediatr Endocrinol Diabetes Metab ; 27(2): 134-140, 2021.
Artigo em Inglês | MEDLINE | ID: covidwho-20234510
ABSTRACT
Metformin is a widely used biguanide drug recommended as a first-line antidiabetic for type 2 diabetes. Currently, metformin is used not only in the treatment of diabetes but also in other diseases. Some studies have shown that metformin causes weight loss in insulin-sensitive and insulin-resistant overweight and obese patients. Metformin is an effective and safe option for women with gestational diabetes and type 2 diabetes in pregnancy, and it may also increase the ovulation rate in patients with polycystic ovary syndrome (PCOS). Longer survival times have been observed in cancer patients using metformin. Metformin has been shown to significantly correlate with lower mortality in obese or type 2 diabetic women hospitalized for COVID-19. It also has a protective effect on the development and progression of many types of cancer. The mechanisms of action of metformin are complex and still not fully understood. Metformin has been shown to act through both AMP-activated protein kinase (AMPK)-dependent mechanisms and AMPK-independent mechanisms. This paper presents the benefits of using metformin in the treatment of various diseases.
Assuntos
Palavras-chave

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / COVID-19 / Metformina Tipo de estudo: Estudo prognóstico Limite: Feminino / Humanos / Gravidez Idioma: Inglês Revista: Pediatr Endocrinol Diabetes Metab Assunto da revista: Endocrinologia / Metabolismo / Pediatria Ano de publicação: 2021 Tipo de documento: Artigo País de afiliação: Pedm.2021.107166

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / COVID-19 / Metformina Tipo de estudo: Estudo prognóstico Limite: Feminino / Humanos / Gravidez Idioma: Inglês Revista: Pediatr Endocrinol Diabetes Metab Assunto da revista: Endocrinologia / Metabolismo / Pediatria Ano de publicação: 2021 Tipo de documento: Artigo País de afiliação: Pedm.2021.107166